Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06593964
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-06
Brief Title:
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma A Prospective Multicenter Randomized Controlled Non-inferiority Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC
Detailed Description:
This is a prospective multicenter randomized controlled non-inferiority design trial Participants who meet the criteria will be randomly assigned into the experimental group or the control groupwith a ratio of 11 In the experimental group the Thermosensitive Nanogel Embolic Agent will be used in the TACE procedure while in the control group the Embosphere microspheres will be used The primary endpoint is disease control rate of the target lesions at 1 month after the last TACE treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None